Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 7/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.35 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | AKT2 | P31751 | 2/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158715 | 0.79 | ALDH1A1 (0.34) | CES2 | |
| SCHEMBL10158747 | 0.74 | ALDH1A1 (0.46) | TLR2PAOXLPAR1LPAR3LPAR6 | |
| SCHEMBL10158716 | 0.73 | AKT1 (0.31) | AKT1 | |
| SCHEMBL10158702 | 0.71 | ALDH1A1 (0.37) | LPAR1LPAR3LPAR6LPAR4LPAR5 | |
| SCHEMBL10158713 | 0.71 | ALDH1A1 (0.41) | — | |
| SCHEMBL10158718 | 0.70 | ALDH1A1 (0.48) | LPAR1LPAR3LPAR6LPAR4LPAR5 | |
| SCHEMBL10158689 | 0.70 | ALDH1A1 (0.43) | — | |
| SCHEMBL13445921 | 0.69 | CES2 (0.34) | LPAR1LPAR3LPAR6LPAR4LPAR5 | |
| SCHEMBL10158708 | 0.69 | TSHR (0.31) | — | |
| SCHEMBL10158711 | 0.69 | LMNA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130195954-A1 | FILMS AND PARTICLES | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2013-08-01 | — | — | US | disclosed |
| US-8338492-B2 | Films and particles | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8334324-B2 | Films and particles | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120107365-A1 | FILMS AND PARTICLES | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110152305-A1 | FILMS AND PARTICLES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7671095-B2 | Films and particles | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080075718-A1 | Films and Particles | THE TRUSTEES OF THE BOSTON UNIVERSITY | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152305-A1 | FILMS AND PARTICLES | APOB, PGF, ACTB | TLR2 4114/4885PAOX 672/4885LPAR1 1089/4885 |
| US-20130195954-A1 | FILMS AND PARTICLES | APOB, PGF, ACTB | TLR2 4114/4885PAOX 672/4885LPAR1 1089/4885 |
| US-20080075718-A1 | Films and Particles | APOB, PGF, ACTB | TLR2 4114/4885PAOX 672/4885LPAR1 1089/4885 |
| US-20120107365-A1 | FILMS AND PARTICLES | APOB, PGF, ACTB | TLR2 4114/4885PAOX 672/4885LPAR1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.